Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage I papillary thyroid cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-12064, NCI-2012-01700, NCCNGSK20008, NCT01723202
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00554, 2012C0101, RU241210I, OSU 12154, 9312, N01CM00039, N01CM00070, N01CM00071, N01CM00099, P30CA016058, NCT01811212
Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 to 70
Sponsor: NCI, Other
Protocol IDs: UW13115, NCI-2014-00833, R01CA176911, P30CA014520, 2014-0391, NCT02138214
Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: 150105, 15-C-0105, NCT02408887
Measuring Patient Expectations for Thyroid Surgery
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-087, NCT01412762
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
Phase: No phase specified
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HIC1312013168, NCT01974284
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-031, NCT02145143
Start Over